Gene therapy is a promising therapeutic alternative for Lysosomal Storage Disorders (LSD), as it is not necessary to correct the genetic defect in all cells of an organ to achieve therapeutically significant levels of enzyme in body fluids, from which nontransduced cells can uptake the protein correcting their enzymatic deficiency. Animal models are instrumental in the development of new treatments for LSD. Here we report the generation of the first mouse model of the LSD Muccopolysaccharidosis Type IIID (MPSIIID), also known as Sanfilippo syndrome type D. This autosomic recessive, heparan sulphate storage disease is caused by deficiency in N-acetylglucosamine 6-sulfatase (GNS). Mice deficient in GNS showed lysosomal storage pathology and loss of lysosomal homeostasis in the CNS and peripheral tissues, chronic widespread neuroinflammation, reduced locomotor and exploratory activity and shortened lifespan, a phenotype that closely resembled human MPSIIID. Moreover, treatment of the GNS-deficient animals with GNS-encoding adeno-associated viral (AAV) vectors of serotype 9 delivered to the cerebrospinal fluid completely corrected pathological storage, improved lysosomal functionality in the CNS and somatic tissues, resolved neuroinflammation, restored normal behaviour and extended lifespan of treated mice. Hence, this work represents the first step towards the development of a treatment for MPSIIID.
Introduction
The term Mucopolysaccharidoses (MPS) encompasses a series of rare metabolic diseases, with either recessive or X-linked inheritance, characterized by defective degradation of mucopolysaccharides -also known as glycosaminoglycans (GAG)-due to mutations that affect the activity of lysosomal hydrolases. As a result of this catabolic blockage, the undegraded GAG accumulates in the lysosomes of cells; the MPS disorders hence belong to the group of Lysosomal Storage Diseases (LSD). The lysosomal dysfunction leads to multisystemic disease, which in certain cases compromises the central nervous system (CNS), causing progressive neurodegeneration. MPS Type III, or Sanfilippo Syndrome, groups the 4 MPS diseases (MPSIIIA-D) that specifically accumulate the GAG heparan sulphate (HS). MPSIIID in particular is caused by the deficiency in the activity of the enzyme N-acetylglucosamine 6-sulfatase (GNS, EC 3.1.6.14). MPSIIID is the least frequent of the 4 MPSIII (1,2), with apparently a higher than average prevalence in patients of Italian and Turkish origin (3) . Several causative mutations have been identified, including missense and nonsense mutations, splice site mutations, frame shifts and small deletions as well as complex rearrangements and gross deletions (3) (4) (5) (6) (7) (8) .
Although the pace at which disease progresses can be heterogeneous amongst MPSIIID patients, all seem to follow the general pattern of Sanfilippo syndrome characterized by progressive CNS degeneration accompanied by relatively mild somatic disease (9) . Children affected by MPSIIID appear normal at birth and parents generally do not suspect the disease until developmental delay becomes apparent. With time, the disease progresses to restless behaviour, hyperactivity, sleep disorders, loss of speech and, later, of psychomotor skills, loss of contact with the environment and, eventually, mental retardation (5, 10, 11) . In addition to neurological symptoms, other nonneurological comorbidities include upper respiratory tract infections, hirsutism, macrocephaly, hepatosplenomegaly, reduced joint mobility and coarse facial features (5, 7, 11, 12) . In late-stage MPSIIID, patients become chair-bound or completely bedridden, and die generally within the 2 nd -3 rd decade of life (3) . There is no approved treatment for MPSIIID and the management of affected patients is just symptomatic. Monogenic diseases are the ideal candidates for gene therapy. Lysosomal diseases caused by deficiency in soluble lysosomal enzymes represent, in theory, a very amenable indication as soluble lysosomal enzymes tagged with Mannose-6-phosphate (M6P) moieties during synthesis can be taken up from the extracellular milieu through endocytosis mediated by M6P receptors located on the plasma membrane (13) . This eliminates the need for correcting the genetic defect in all cells of an affected organ, as non-transduced cells can be cross-corrected by enzyme secreted to body fluids by transduced cells. Three main in vivo gene therapy strategies have been developed so far for the treatment of diseases that course with neurodegeneration. The first approach is based on the direct injection of the vector into the brain parenchyma (14, 15) currently being tested in Phase I/II trials for MPSIIIA (NCT02053064, www.clinicaltrials. gov; date last accessed February 24, 2017) and IIIB (ISRCTN19853672, www.isrctn.com; date last accessed February 24, 2017) . Multiple injections are required to overcome the limited diffusion of the vector from the site of injection, complicating the surgical procedure (16) . The second alternative exploits the ability of serotype 9 Adeno-associated viral (AAV) vectors to cross the blood-brain barrier (BBB) and transduce the CNS when delivered intravenously (17) (18) (19) . Full disease correction has been reported in MPSIIIA and B mice (20, 21) , and a clinical trial is currently ongoing for the former (NCT02716246, www.clinicaltrials. gov; date last accessed February 24, 2017) . The threshold vector dose necessary to achieve therapeutically meaningful CNS transduction is, however, quite high. Finally, the delivery of vectors directly to the cerebrospinal fluid (CSF) for distribution to the whole CNS allows for a great reduction in vector load (20, 22) . Besides leading to higher ratios of CNS sulfamidase activity per AAV vector genome (vg) injected, the passage of AAV vectors from the CSF to the bloodstream also leads to liver transduction at levels sufficient to correct somatic pathology (22) . This strategy has been successfully applied by us and others to MPSIIIA (22) , IIIB (23), I (24), II (25, 26) and VII (27) .
The development of successful therapeutic strategies for a given disease depends a great deal on the availability of good animal models of disease. Here, we report the generation of the first mouse model of MPSIIID. Moreover, along with full characterization of the biochemical, histological and functional abnormalities caused by the knockdown of the Gns gene in mice, we demonstrate the therapeutic efficacy of a gene therapy approach based on the delivery to the CSF of AAV9 vectors encoding for GNS. Our study represents the first step towards the development of a gene therapy treatment for this devastating disease.
Results

Generation of a GNS-deficient animal model
To generate a novel animal model of human MPSIIID, we used embryonic stem cells (ESC) carrying a disruptive insertion between exons 5 and 6 of the Gns gene (Supplementary Material, Fig. S1A ) available through the International Mouse Phenotyping Consortium (IMPC, www.mousephenotype.org; date last accessed February 24, 2017) . The generation of animals with disrupted Gns was confirmed by PCR genotyping, which evidenced a different pattern of bands for WT (Gns
) and homozygous (Gns -/-) mice (Fig. 1A) . The disruption of the Gns gene was not embryonically lethal and at birth Gns-deficient mice were viable and completely indistinguishable from WT and heterozygous littermates. Homozygous mice were born according to the expected Mendelian inheritance ratios.
Gns transcripts were barely detectable in brain and liver samples from Gns -/-mice, confirming the successful disruption of Gns expression (Fig. 1B) . As expected, heterozygous mice presented $50% of Gns expression compared to wild-type littermates (Fig. 1B) . In agreement with the dramatic drop in Gns transcripts, the enzymatic activity of GNS was practically undetectable in the brain and liver of Gns -/-animals ( Fig. 1C ).
Brain lysosomal pathology and neuroinflammation in GNS-deficient animals
Excessive GAG storage is the main pathological characteristic of all forms of MPS disease, including MPSIIID (28). At 2 months of age, GNS-deficient male mice showed accumulation of GAGs in all brain regions analyzed, with increases ranging from 15% to 50% over values observed in healthy littermates (Fig. 1D ). Similar observations were made in females (Supplementary Material, Fig. S1B ). To further characterize our animal model we performed immunohistochemical detection of the lysosomal marker lysosomal-associated membrane protein 2 (LAMP2) on brain sections of 2-month-old animals. In agreement with GAG data, we quantified a statistically significant increase in the intensity of LAMP2 signal in several CNS regions of Gns -/-male and female mice (Fig. 1E, Supplementary Material, Fig. S1C ), evidencing an increase in the number and/or size of CNS lysosomes in these animals. Moreover, electron microscopy analysis in the brains of Gns -/-mice showed large electrolucent vacuoles consistent with lysosomes loaded with GAGs in the cytoplasm of perineuronal glial cells (Fig. 1F) . To determine the age of onset of the disease in the CNS, an immunostaining against LAMP2 in 1-and 4-week-old Gns -/-mice was performed.
Relevant signs of lysosomal distention were only detected at 4 weeks, in agreement with the progressive course of the disease (Supplementary Material, Fig. S2 ). The presence of astrogliosis and microgliosis, namely neuroinflamation, is a characteristic of the brains of animal models and humans affected by mucopolysaccharidoses with CNS compromise (29) (30) (31) (32) (33) . We then stained sections of the encephalon of 2-month-old male and female mice with an antibody directed against glial fibrillary acidic protein (GFAP), whose expression is upregulated in activated astrocytes (34) , and with Bandeiraea simplicifolia isolectin B4 (BSI-B4), which under our staining protocol binds to activated microglia (35) . The frontal, parietal and occipital cortices, as well as the superior colliculus and thalamus of GNS-deficient mice of both genders showed strong GFAP ( Fig. 2A, Supplementary Material, Fig. S3A ) and BSI-B4 (Fig. 2B,  Supplementary Material, Fig. S3B ) positive signal, confirming the presence of astrocytosis and microgliosis in GNS-deficient mice at 2 months of age. Moreover, immunostaining against GFAP and BSI-B4 also showed the progressive onset of neuroinflammation in GNS-deficient mice since the first signs of astrocytosis and microgliosis were already observed at 4 weeks of age (Supplementary Material, Fig. S4 ).
Systemic disease in GNS-deficient animals
The disruption of the Gns gene also led to pathological accumulation of GAGs in several peripheral organs, most especially in liver, kidney or spleen, in which GAG content was several fold higher than in healthy male and female WT animals (Fig. 3A,  Supplementary Material, Fig. S5A) . Likewise, the analysis of the size of the lysosomal compartment by immunohistochemistry for the lysosomal marker Lysosomal Associated Membrane Protein 1 (LAMP1) showed lysosomal distension in the liver, heart, lung, kidney and urinary bladder of Gns -/-mice ( Results are shown as mean 6 SEM of 3-5 animals/group. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 versus WT.
n.d; non-detectable.
increase in Gns -/-mice (Fig. 3C ). These observations were in agreement with the presence of somatic pathology in patients affected by MPSIIID disease (28) .
Correction of brain storage pathology by intra-CSF delivery of GNS-encoding vectors
Having characterized the storage pathology in 2-month-old GNS-deficient mice, we set out to study the disease in older animals while in parallel test the potential therapeutic efficacy of delivering AAV9 vectors encoding for GNS to the CSF of these animals. To this end, we generated an AAV9 vector carrying an optimized version of the murine Gns coding sequence under the control of the ubiquitous CAG promoter (AAV9-Gns). A dose of 5Â10 10 vector genomes (vg) of AAV9-Gns was administered to 2-month-old Gns -/-mice through cisterna magna injection, as the cisterna constitutes an easy route of access to the CSF of experimental animals (22, 36, 37) . A similar dose of non-coding AAV9-Null vectors was injected as a control. As expected, untreated and Null-injected Gns -/-mice showed almost undetectable GNS activity in brain extracts at 6 months of age (Fig. 4A) .
Administration of therapeutic AAV9-Gns vectors led to a considerable increase in brain GNS activity, which reached $75% of WT levels 4 months after vector administration (Fig. 4A) , and remained at similar levels after 20 months (Supplementary Material, Fig. S6A ). At 6, 12 and 22 months of age, i.e. 4, 10 and 20 months after vector administration, animals were sacrificed and multiple pathological traits of MPSIIID were analysed. As soon as 4 months after vector delivery, the restoration of GNS activity had already substantially reduced GAG content throughout the encephalon, which by 12 and 22 months of age showed GAG levels indistinguishable from those documented in healthy animals ( In AAV9-Gns-treated mice of both genders, the reduction in the accumulation of GAGs observed after gene transfer translated into a drop in LAMP2 positive signal to almost WT levels in different areas of the encephalon ( Fig. 4C and D, Supplementary Materials, Figs. S6C, S7B and C, S8A), indicating shrinkage of the lysosomal compartment as GAG levels normalized. The ultrastructural analysis by transmission electron microscopy of the cerebral cortex of 6-month-old male mice revealed the presence in Null-injected GNS-deficient mice of large vacuoles containing electrolucent substance in the cytoplasm of cells identified as perineuronal glial cells. These vesicles, which appeared to be lysosomes filled with storage material, were completely absent in samples from healthy wild-type or AAV9-Gns-treated Gns -/-animals ( Fig. 5A ), confirming the restoration of the normal size of the lysosomal compartment following gene transfer. In LSD, the loss of lysosomal homeostasis can end up affecting the activity of other lysosomal enzymes different from the one directly affected by the gene mutation (23, 25, 29, 38) . In brain extracts obtained from 6-month-old untreated male and female GNS-deficient mice, the activities of galactosamine (N-acetyl)-6-sulfatase (GALNS), b-glucuronidase (GUSB) and b-hexosaminidase (b-HEXO) were altered, albeit not in the same direction (Fig. 5B , Supplementary Material, Fig. S9 ). In the case of GALNS, activity was decreased in untreated Gns -/-mice of both genders, while GUSB and b-HEXO showed activity levels that were $2-fold higher than those documented in wild-type littermates. Treatment of GNS-deficient male and female mice with AAV9-Gns vectors led to the normalization of GALNS activity and a marked reduction in the activities of GUSB and b-HEXO, measured 4 months after vector delivery, evidencing the reinstatement of lysosomal homeostasis in the CNS of treated animals ( 
Long-lasting eradication of neuroinflammation by single delivery of intra-CSF gene therapy
When astrogliosis and microgliosis were analyzed 4, 10 or 20 months post vector administration, i.e at 6, 12 or 22 months of age, GNS-deficient male and female mice that had received AAV9-Gns vectors showed a remarkable reduction in GFAP signal intensity in all brain areas studied, as demonstrated by morphometric analysis ( Fig. 6A and B, Supplementary Materials, Figs. S6D, S8B, S10A). Similarly, treatment with GNS-encoding vectors reduced BSI-B4 positive signal to levels almost as low as those quantified in wild-type healthy animals ( Fig. 7A and B, Supplementary Materials, Figs. S6E, S8C, S10B). Importantly, this profound effect on neuroinflammation was maintained up to 20 months after a single delivery of the therapeutic vector to animals that had already established disease at the time of treatment.
Delivery of GNS-encoding vectors to the CSF of GNSdeficient mice rescues somatic MPSIIID pathology
Once administered to the CSF of small and large animal models, including non-human primates (NHP), AAV9 vectors can reach the bloodstream and transduce the liver (22, 23, 25, (39) (40) (41) . In agreement with this, the administration of AAV9-Gns to the CSF of GNS-deficient male mice led to a substantial increase in liver GNS activity, reaching values $20-fold over those observed in healthy wild-type mice (Fig. 8A) . Consequently, GAG content was completely normalized in the liver of 6-, 12-and 22-month-old treated animals ( *P < 0.05, **P < 0.01 and ***P < 0.001 versus AAV9-Null-injected group. n.d, non-detectable.
When overexpressed in the liver, soluble lysosomal proteins are efficiently secreted to the bloodstream, turning this organ into a source of circulating enzyme (42) . In the serum of GNSdeficient mice treated with AAV9-Gns vectors, GNS activity was 20-fold higher than in wild-type littermates (Fig. 8D) . Through M6P receptors, lysosomal enzymes can be taken up from the circulation by organs that are not efficiently transduced by the vector (25) . Four months after AAV9-Gns delivery, GNS-deficient mice of both genders showed normal or almost normal content of GAGs in spleen, kidney, heart, lung and adipose tissue, and the therapeutic effect persisted 20 months after treatment (Fig.  8E, Supplementary Material, Fig. S11C) . Likewise, the analysis of the size of the lysosomal compartment by immunohistochemistry for the lysosomal marker LAMP1 showed lysosomal distension in the liver, heart, lung and urinary bladder of untreated or Null-treated 6-month-old Gns -/-mice (Fig. 9A, Supplementary Material, Fig. S11D ). By contrast, Gns -/-animals that received a single administration of AAV9-Gns vectors into de CSF showed a marked reduction in LAMP1 signal intensity; the appearance of the immunostained tissue sections obtained from treated animals was very similar to that of healthy wild-type littermates (Fig. 9A, Supplementary Material, Fig. S11D ). Finally, we used transmission electron microscopy to evaluate the efficacy of gene therapy at the ultrastructural level. Six-month-old AAV9-Null-injected GNS-deficient mice presented a large number of electrolucent vacuoles within their hepatocytes and bronchial ciliated cells of the lung, whereas healthy WT and AAV9-Gnstreated mice did not (Fig. 9B ). Consistent with a complete clearance of pathological HS accumulation and normalization of lysosomal compartment size, the liver of GNS-deficient animals treated with therapeutic vector showed normal levels of activity of other lysosomal enzymes not affected by mutation and involved in the catabolism of HS, such as alpha-L-iduronidase (IDUA), N-sulfoglucosamine sulfohydrolase (SGSH), a-N-acetylglucosaminidase (NAGLU), heparan-a-glucosaminide N-acetyltransferase (HGSNAT) or unrelated to the HS pathway, such as GALNS, GUSB, and b-HEXO (Fig. 10, Supplementary Material, Fig.  S12 ). The activity of these enzymes was already perturbed at the age of treatment, i.e. in young 2-month-old animals (Fig. 10,  Supplementary Material, Fig. S12 ), demonstrating the disruption of lysosomal homeostasis early in the development of the disease, and the reversal of this condition with the gene therapy treatment.
Altogether, these results demonstrate that a single administration of AAV9-Gns vectors to the CSF of 2-month-old Gns -/-mice is sufficient to completely correct the somatic pathology characteristic of the MPSIIID animal model.
Intra-CSF gene therapy corrects behavioural alterations and prolongs survival of GNS-deficient mice
One of the main features of Sanfilippo disease is the presence of profound behavioural disturbances, which manifest initially as hyperactivity and aggressiveness, and slowly disappear as mental retardation progresses (1). To evaluate if the deficiency in GNS induced any behavioural changes in this new mouse model, the Open Field test was performed on naïve 2-, 6-and 12-month-old Gns -/-male animals. At the age of 2 months, no behavioural differences were detected in GNS-deficient mice when compared to healthy WT (data not shown). As animals grew older, however, behavioural disturbances became apparent: mice with GNS deficiency travelled less distance, spent more time resting and reared less on their hindlimbs than their healthy counterparts (Fig. 11A) , which was suggestive of hypoactive and less exploratory behaviour. By contrast, GNSdeficient mice that received an intra-CSF administration of AAV9-Gns vectors at 2-month-old and that were tested in the Open Field at 6 or 12 months of age behaved as healthy wildtype littermates (Fig. 11A) , indicating that the behavioural alterations induced by the genetic defect in the Gns gene had been corrected by the intra-CSF administration of GNS-encoding AAV9 vectors.
Finally, the effect of GNS deficiency on lifespan was assessed. Untreated and Null-injected Gns -/-mice showed a median survival of 16.3 and 15.9 months, respectively (Fig. 11B ), in agreement with the shortened lifespan reported for MPSIIID patients (3). In contrast, GNS-deficient mice treated with therapeutic vector were still alive by 22 months, the latest data point available for this cohort, indicating that our gene therapy considerably prolonged the survival of GNS-deficient mice (Fig. 11B ).
Discussion
Procuring efficacious treatments for the large number of untreated rare diseases represents a challenge for the scientific and medical communities. If the medical plausibility exists, the development of new treatments should be attempted, however rare a disease may be. Although common therapeutic strategies may be applied to diseases that share pathophysiological traits, each disease presents its own peculiarities and efficacy needs to be tested in appropriate animal models to support clinical success. We report here the generation of the first mouse model of MPSIIID and the complete correction of disease following intra-CSF gene therapy with AAV9 vectors. Mice that carried disruption of the Gns gene in homozygosis showed a phenotype that recapitulated human MPSIIID (28) . The deficiency in GNS activity led to marked accumulation of total GAGs at 2 months of age, with the first signs of lysosomal distention at about 1 month of age. The accumulation of GAGs was evident in the CNS and in peripheral organs, most notably in the liver, but was also present in the spleen and kidney at considerable levels. Excessive storage of undegraded GAGs enlarged the lysosomal compartment and altered the activity of other lysosomal hydrolases, evidencing the loss of lysosomal homeostasis. The deregulation of the activity of other lysosomal enzymes aside that affected by the mutation is a common finding in other animal models of LSDs (23) (24) (25) (26) (27) 29) . These alterations could be attributed to the activation of the transcriptional factor EB (TFEB), a master regulator of lysosomal function that boosts the expression of genes related to cellular clearance and lysosomal hydrolases (38) . In agreement, GNS-deficient mice showed an upregulation in all enzymatic activities measured with the exception of GALNS, a finding that we have also observed in other MPSs (25, 29) . Some lysosomal hydrolases are inhibited by the excessive accumulation of substrates. In particular, GALNS is described to be inhibited by increased storage of HS (43) and this may be responsible of the increased levels of keratan sulphate, a substrate of GALNS, observed in the plasma of human patients of several LSDs (44) . Neuroinflammation, characterized by activation of CNS astrocytes and microglial cells, was present throughout the encephalon of affected mice. Neuroinflammation is pathognomonic of neurodegenerative diseases (45, 46) and is believed to play a key role in the pathogenesis of MPSIII (23, (31) (32) (33) 47) . In gene profiling studies that we previously performed in mice affected by MPSIIIB or MPSII, the vast majority of genes that were found to be differentially expressed in the brain had gene ontologies associated with inflammation and innate immunity (23, 25) . Moreover, when the contribution of different cells to the observed changes in transcript levels was analysed, microglial cells were by far the most and AAV9-Gns-treated mice were analysed at 22 months of age, because all untreated and AAV9-Null injected GNS-deficient mice were dead by this age. Scale bars: 50 mm; insets, 20 mm. Results are shown as mean 6 SEM of 3-5 animals/group. ***P < 0.001 versus AAV9-Null-injected group.
represented cell type, emphasizing the role that microglia might be playing in MPS brain disease (23, 25) . By 2 months of age, biochemical and histological findings had not yet translated into functional deficits, but reduced locomotor and exploratory activity were consistently detected in animals 6 months and older, as demonstrated in the Open Field test. Finally, the new animal model showed considerably reduced life expectancy; almost all animals were dead before 20 months of age. The phenotype of this new mouse model closely resembled that observed in the other mouse models of Sanfilippo syndrome, since it showed similar alterations of biochemical, histopathological and behavioural parameters and also shortened lifespan (22, 23, 29) . Nevertheless, each mouse model of MPSIIIA-D presented differences in the time at onset and severity of the pathology, i.e. GAG build-up, the degree of lysosomal distention, the severity of neuroinflammation, the onset of behavioural disturbances and lifespan differed depending on the Sanfilippo animal model (29) . Although Enzyme Replacement Therapies (ERT) have provided valid therapeutic options for LSD that affect somatic organs (VIMIZIN V R , BioMarin; NAGLAZYME, BioMarin), the presence of the BBB limits their applicability to LSD that present with neurodegeneration. Accordingly, when recombinant caprine GNS was infused intravenously to a goat affected by MPSIIID, liver pathology was corrected, but no improvements were observed in the encephalon due to fractional penetration of the recombinant enzyme to the CNS (48) . To bypass the BBB, ERT can be supplied directly to the CSF through, for example, an Intrathecal Drug Delivery Device (IDDD). Yet, a recent ERT clinical trial for MPSII has put in evidence the inconveniences associated with the implantation of such devices for periodic delivery of proteins to the CNS; 85% of the reported serious adverse events of this study were related to the IDDD, which required surgical revision or removal in half of the patients (49) . Other drawbacks of ERT include the potential risk of lifethreatening allergic reactions during product infusion and the discomfort that performing periodic long intravenous administrations supposes to paediatric patients.
In contrast, gene therapy can offer production of the deficient enzyme directly in the CNS after a single intervention expected to provide lifelong clinical benefits. Biffi and colleagues have shown remarkable clinical benefits when treating patients affected by the LSD metachromatic leukodystrophy after ex vivo transduction of autologous CD34þ hematopoietic stem cells with integrating lentiviral vectors (50, 51) . After re-infusion of the genetically modified cells to the patient, the enzyme is expressed in cells of hematopoietic lineages, some of which colonize the CNS to differentiate into local microglia (52) . Although promising, the use of integrating viral vectors as well as the requirement for myeloablating conditioning prior to the infusion of the product still pose potential risks to the patients (53) (54) (55) . The use of AAVs in vivo is, on the other hand, supported by a large number of clinical trials in which these vectors have been repeatedly demonstrated to have an excellent safety profile (56) (57) (58) (59) . AAVs are predominantly non integrating viruses that mediate transduction of several cell types and provide long-term expression of the protein of interest provided the transduced cell does not undergo division (59, 60) . Indeed, data from early haemophilia clinical trials have demonstrated more than 10 years of production of factor IX (FIX) from the muscle of patients that received an intramuscular injection of serotype 2 AAV vectors (61) . In addition, most-commonly used AAV serotypes have relatively fast kinetics of transgene expression, with detection of gene product in body fluids within days of product administration (22, 23) . This may represent an additional advantage of AAV-mediated in vivo approaches, particularly in the case of rapidly progressing forms of disease in which ex vivo gene therapy seems to be less efficacious (51) . We were the first to demonstrate that delivery of AAV9 vectors carrying the sulfamidase gene to the CSF of MPSIIIA mice was a feasible strategy for treating lysosomal pathologies that present with neurodegeneration, with the additional advantage that -at least in mice and dogs-the passage of vector to the circulation results in transduction of the liver, opening the possibility for simultaneous correction of central and somatic disease at doses much lower than those required when the vector is delivered systemically (22, 62) . Similar correction of pathological signs was observed after intra-CSF administration of AAV9-Naglu or AAV9-Ids vectors to MPSIIIB or MPSII mice (23, 25) . This approach has also been reported successful to treat MPSI and VII animal models (27, 63 ). An additional advantage of intra-CSF delivery over intravenous infusion is that transduction is not limited by anti-AAV seropositivity because the BBB maintains the concentration of immunoglobulins in the CSF very low, even in seropositive patients with advanced MPS disease (22) . This is worth emphasizing as concentrations of neutralizing antibodies as low as 1/5 can completely block transduction when vectors are administered systemically (23, 64) , and seropositivity, albeit lower in children than in adults (65), could prevent a significant number of patients from receiving intravenous AAV treatment.
The administration of GNS-encoding AAV9 vectors to 2-month-old GNS-deficient mice led to significant levels of GNS activity in the CNS, complete normalization of GAG catabolism, disappearance of lysosomal distension and restoration of lysosomal homeostasis in animals of both genders. When the intensity of GFAP and BSI-B4 staining in different parts of the brain was compared with untreated MPSIIID mice and mice that received either Null or therapeutic vectors, it became evident that neuroinflammation had almost disappeared with the treatment. Moreover, the efficacy of our treatment persisted longterm, i.e. 20 months after a single administration of the AAV9-Gns vectors to the CSF.
The extensive degree of disease correction reported here was achieved with levels of GNS activity in the brain of AAV9-Gns-treated animals that, although quite high, did not reach those documented in healthy littermates. The observation that the lysosomal pathology was, nevertheless, completely corrected in treated animals agrees with the notion that complete restoration of normal activity is not required to obtain a significant clinical benefit in all LSD, as there seems to be a generally low threshold of enzymatic activity above which cells can cope with substrate catabolism (66) . The dose used in the present work was chosen based on our previous experience in CNSdirected gene therapy in other forms of MPS, Sanfilippo types A and B and Hunter syndrome (22, 23, 25) . Further studies are warranted to establish the minimally effective dose in this MPSIIID animal model.
Disease correction was achieved throughout the encephalon. We and others have previously demonstrated in small and large animal models, including NHP, that when AAV9 vectors are delivered to the CSF, this fluid acts as a carrier that distributes the vectors throughout the CNS (22, 23, 40, 41) . This can be attained through a single burr hole, and following a surgical technique -ventriculostomy-with very well-characterized risks and complications and amenable to all neurosurgeons in lowcomplexity hospitals (67) . Following intra-CSF delivery to dogs, we observed efficient transduction of superficial and deep cerebral structures, as well as transduction of the whole spinal cord up to the cauda equina, and of the peripheral nervous system with high positivity in cervical, dorsal and lumbar dorsal root Values are expressed as mean 6 SEM of 5 animal/group. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 versus either WT or AAV9-Null-injected group.
ganglia (22) . Indeed, the enzymatic activity was largely increased in the CSF of dogs after intra-CSF delivery of AAV9 vectors encoding for soluble lysosomal enzymes (22, 23) . Importantly, activity levels have remained elevated for >4 years, with observation ongoing, in the absence of any signs of toxicity (F. Bosch, unpublished data). Given that soluble lysosomal enzymes can be taken up from the extracellular compartment through M6P receptors present on their plasma membrane, the presence of the enzyme in the circulating CSF guarantees availability of the protein to cells located in any structure the CSF might reach. Thus, aside from having a much simpler and standardized surgical procedure, intra-CSF delivery is associated with considerably better vector and transgene product distribution than other ways of providing vectors to the CNS, such as delivery by multiple intra-parenchymal injections (16, 68, 69) . Cross-correction also underlies the clearance of excessive GAG storage form peripheral tissues. Despite the fact that after delivery of vectors to the CSF the liver is the only organ efficiently transduced (22, 23, (25) (26) (27) 39, 40) , hepatocytes can produce large quantities of enzymes that are secreted to the bloodstream (22, 23, 25) . Indeed, following treatment of MPSIIID mice with therapeutic vector, there was a remarkable correlation between the levels of GNS activity documented in the liver and in serum ($2000% of WT levels in both cases). Similar correlations were previously observed in other forms of MPSIII (22, 23) . Following delivery of similar doses of AAV9 vectors encoding for the corresponding enzymes to the CSF of animal models of MPS, a common observation in our hands has been that, while the levels of activity in the CNS are less than 100% of WT activity ($40-70% depending on the model) the activities reached in the liver are several fold higher than WT levels (22, 25) . An exception to this was the gene transfer of Naglu, which resulted in supraphysiological levels of NAGLU both in the brain and in the liver ($800% of WT levels). The higher activity levels in the liver over brain were supported by the vector genome copy number data, which showed there were more vector genomes in the liver than in the brains of all treated animals, irrespective of the model, despite the fact that the vectors were delivered to the CNS. These observations are ultimately reflecting the high tropism that AAV9 vectors have for the liver (23, (25) (26) (27) 39, 40) . Importantly, in all animal models in which intra-CSF delivery of AAV9 vectors led to supraphysiological levels of the enzyme, no sign of toxicity was ever detected. Moreover, the presence of enzyme in the circulation ensures availability to all peripheral tissues and organs. In MPSII mice treated with a similar approach, we documented significant levels of IDS activity in the lungs and, in particular, in the heart, even though these organs showed almost undetectable vector genome copy numbers (25) .
Finally, the correction of disease at both neurologic and somatic level translated in the disappearance of behavioural disturbances -clearly identifiable in untreated MPSIIID cohortsand in a considerable extension of lifespan. These results confirm the therapeutic potential of the intra-CSF administration of AAV9 vectors. They also extend the body of data published on this approach to a new model, the MPSIIID.
In conclusion, we have succeeded in generating a rodent animal model deficient in GNS that closely recapitulates human MPSIIID. Furthermore, we provide solid evidence supporting the use of GNS-encoding AAV9 vectors delivered to the CSF as a therapeutic option for this disease. This initial proof-of-concept study paves the way for the future clinical development of the approach for the treatment of MPSIIID in humans. 
Materials and Methods
Animals
Sample collection
Mice were anesthetized by Intraperitoneal (IP) injection (100 mg/ kg ketamine and 10 mg/kg xylazine). Blood was extracted following cardiac puncture and animals were then transcardially perfused with 12 ml of PBS to wash out the blood. The encephalon and somatic organs were dissected and stored at -80 C or fixed in formalin.
Gns expression
Brain and liver total RNA were obtained using the RNeasy Mini Kit (Qiagen), following the manufacturer's instructions, and retrotranscribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche). Endogenous Gns expression was assessed through quantitative real-time PCR using specific primers (Fw: 5'-AACT ACACCCTCTCCATCAAC-3', Rv: 5'-GGCTCAGAGTTGGACTTGTA-3') and probe (5'-/56-FAM/CCTGACAGA/ZEN/TGTTCTGGCCAAC CT/3IABkFQ/-3') that amplify a region spanning the junction of exons 5 and 6 of the murine Gns gene. Values were normalized to the expression of murine Rplp0 (Fw: 5'-GGGCCTGCACTCTCG CTTT-3', Rv: 5'-TGCCAGGAGGCGCTTGT-3'). Real-time PCR was performed in a Light CyclerV R 480 (Roche) using the Light Cycler 
Activity of lysosomal enzymes
Protein extracts were obtained by sonication of tissues in 250 (brain) or 500 (liver) ml of Mili-Q water. Serum was analyzed unprocessed. Enzymatic activities were analyzed through standard methods using 4-methylumbelliferone-derived fluoregenic substrates. N-acetylglucosamine-6-sulfatase (GNS) activity was measured in a 2-step assay as previously described (70) . Briefly, 10 ml of serum or 10 mg or 30 mg of the brain or liver extract, respectively, were incubated with 4-methylumbelliferyl-a-N-Ac glucosaminide-6-sulphate sodium salt (Enantia) for 17 h at 37 C.
Then, Pi/Ci buffer (0.4 M Na 2 HPO 4 /0.2 M citric-acid buffer, pH 4.7 þ 0.02% Na-azide) and LEBT solution (Lysosomal Enzymes purified from Bovine Testis, Moscerdam Substrates) were added to the mix and incubated for additional 24 h at 37 C. The reaction was stopped by increasing pH, and released fluorescence was measured with a FLx800 fluorimeter (BioTek Instruments). The enzymatic activities of IDUA, SGSH, NAGLU, HGSNAT, GALNS, GUSB and b-HEXO were determined as previously described (29) . Brain and liver activity were normalized against the total amount of protein, quantified using the Bradford protein assay (Bio-Rad). Serum activity was normalized against volume.
GAG quantification
Tissues were weighted and digested overnight with proteinase K (0.2 mg/ml). Extracts were clarified by centrifugation and filtration (Ultrafree MC, Millipore). The amount of total GAGs in each tissue was quantified with the Blyscan TM Glycosaminoglycan Assay (Bicolor), with chondroitin 4-sulphate used as standard. Values were normalized to wet tissue weight.
AAV production and administration
The optimized coding sequence of murine Gns (GeneArt, Life Technologies) was cloned under the control of the ubiquitous hybrid promoter CAG (CMV enhancer, chicken b-actin promoter, plus portions of chicken b-actin intron 1 and rabbit b-globin intron 2/exon 3) into AAV backbone plasmids. AAV serotype 9 vectors were produced by triple transfection and purified using an optimized cesium chloride gradient-based purification (71) . qPCR was used for titration of AAV9-Gns vectors. A dose of 5Â10 10 vg was administered to the cisterna magna of 2-monthold mice as previously described (22, 72) . Briefly, mice were anesthetized and a 2 mm rostro-caudal incision was made on the posterior part of the shaven head. The animal was kept in a prone position keeping the head at a slightly downward inclination. A Hamilton syringe was introduced between the occiput and the C1-vertebra to deliver 5 ml of vector dilution. All mice received the same vector dose irrespective of gender and body weight.
Histology and electron microscopy
Tissues were fixed for 12-24h in formalin, embedded in paraffin and sectioned. For immunohistochemical detection, sections were incubated with rat anti-LAMP1 (SC-19995, Santa Cruz Biotechnology), rat anti-LAMP2 (ab13524, Abcam) and rabbit anti-GFAP (Z0334, Dako Cytomation). The BSI-B4 lectin (L5391, Sigma) was used to label activated microglia. Images were obtained with an optical microscope (Eclipse 90i, Nikon). Signal intensity was quantified in 4 images of each brain region and 10 images of each urinary bladder per animal at low magnification (20X), which essentially covered the whole area, using the NIS Elements Advanced Research 2.30 software and the same signal threshold settings for all animals. The percentage, in pixels, of positive area was calculated. Samples for transmission electron microscopy were processed as previously described (20) and analyzed with a Hitachi H-7000 transmission electron microscope (Hitachi).
Behavioral assessment
Mouse behavior was analyzed through the Open Field test performed between 9:00 am and 2:00 pm. Animals were placed in the lower right corner of a brightly lit arena (41 Â 41 Â 30 cm) crossed by 2 bundles of photobeams (Panlab) that detect horizontal and vertical movements of the mice. Exploratory and motor activities were recorded during the first 2 min of the test using a video-tracking system (SmartJunior, Panlab).
Statistical analysis
Results are expressed as mean 6 SEM. Statistical comparisons were made using two-tailed Student's t-test for the description of the mouse model, and one-way analysis of variance (ANOVA) with Dunnet's post-test for multiple comparisons to assess the therapeutic efficacy of the treatment. Statistical significance was considered if P < 0.05. Kaplan-Meier curves were used for survival analysis, and the long-rank test was used for comparisons.
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